Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.

AstraZeneca and its wholly owned subsidiary MedImmune will leverage the Hybrozyme platform technology. ALT-B4 therapy ...

Cambridge: AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase ...

The biotechnology corporation Alteogen announced on the 17th that it signed a technology export contract with the global pharmaceutical company Astrazeneca's biopharmaceutical subsidiary MedImmune to ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

To leverage Alteogen's ALT-B4 Hybrozyme platform technology for large volume subcutaneous administration of drugs.

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ...

AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform ...

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme™ platform technology. Under the terms of the agreement, AstraZeneca ...